Guggenheim analyst Vamil Divan lowered the firm’s price target on Merck (MRK) to $122 from $130 and keeps a Buy rating on the shares. The firm is updating its global biopharma coverage forecasts ahead of Q4 earnings following check-ins with investor relations teams and recent public commentary, the analyst tells investors in a preview for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck (NYSE:MRK) and Big Pharma Face Down Wave of Generics in 2025
- Merck CEO: We’re a much broader company than we have been
- Drugmakers to push Trump to pause price negotiations, Bloomberg reports
- Is There an Opportunity in Moderna Stock’s Volatility?
- Drugmakers Raise the Prices on 583 Products to Start 2025